| Methods |
2‐week placebo run‐in; inclusion criteria= 1) sitting DBP=95‐114 mm Hg during last 2 weeks of run‐in, and also on day 0, the first day of active treatment, and 2) mean daytime (0600‐2159h) >/= 85mm Hg by ambulatory BP monitoring; consecutive measurements; 8‐week double‐blind treatment |
| Participants |
Enalapril 10 mg once daily: n=77(32 males,45 females); mean age=55.8(8.7) years; baseline sitting SBP=166.8(14.8) mm Hg, DBP=106.7(4.6) mm Hg;
Placebo: n=77(33 males,44 females); mean age=57.2(9.5) years; baseline sitting SBP=166.4(14.1) mm Hg, DBP=106.9(4.7) mm Hg |
| Interventions |
Enalapril 10 mg once daily,
Placebo;
administered at approximately 8AM |
| Outcomes |
Trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SD of change not reported, endpoint BP and SD reported; imputed endpoint SD for SD of change; BP data from Figure 1, p. 95; Jadad score=4; funding source= Solvay Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
